Dexmedetomidine versus remifentanil in sedation, analgesia, and vital signs in stereotactic brain biopsy: A randomized, single-blind, active-controlled clinical trial Authors: Faranak Behnaz, Parisa Sezari, Mohammad Mirahmadi Eraghi, Narges Bazgir, Sogol Asgari Published: 2026 ABSTRACT ObjectiveStereotactic frame-based brain biopsy is a minimally invasive neurosurgical technique. Dexmedetomidine, an alpha-2 adrenergic agonist, is known to decrease heart rate, blood pressure, and stress response. Remifentanil is a short-acting opioid receptor agonist. This study compared dexmedetomidine and remifentanil with respect to sedation quality, hemodynamic alterations, analgesia, and recovery profiles during stereotactic brain biopsy.MethodsA total of 140 American Society of Anesthesiology class II patients (72 males, 68 females) were enrolled in a single-blind controlled trial. Patients were randomly divided into the remifentanil group and the dexmedetomidine group. Intraoperative monitoring included blood pressure, oxygen saturation, heart rate, and the Ramsay sedation scale. The visual analog scale score and the total morphine consumption were measured in the postanesthesia care unit.ResultsRamsay sedation scale scores were significantly higher in the remifentanil group (p < 0.001). Heart rate, systolic blood pressure, and diastolic blood pressure were significantly higher in the dexmedetomidine group (p = 0.012, p < 0.001, and p < 0.001, respectively). Visual analog scale scores and total morphine consumption were significantly lower in the dexmedetomidine group (p < 0.001 and p < 0.001, respectively).ConclusionsThe remifentanil group achieved a deeper level of sedation. The dexmedetomidine group had higher mean hemodynamic parameters. The visual analog scale scores and the dose of consumed morphine in the postanesthesia care unit were lower in the dexmedetomidine group.Clinical trial registration code: IRCT20210415050983N2 Introduction A biopsy is performed when diagnostic imaging of lesions is insufficient or when open resection is not feasible. It enables the collection of small tissue samples through a minimally invasive procedure, thereby facilitating an accurate diagnosis. Brain biopsy techniques have evolved substantially from invasive freehand craniotomies to stereotactic techniques. Imaging studies facilitate safe and accurate tissue sampling.1–4 Image-based stereotactic, frame-based brain biopsy is one of the most frequently used methods in neurosurgery. It is a minimally invasive and quick procedure.1,2,5,6 The stereotactic approach enables the acquisition of three-dimensional brain images using imaging techniques with fixed or radiopaque sets. 7 However, this technique is associated with severe complications such as neurological impairments, seizures, unconsciousness, and symptomatic and asymptomatic bleeding. 8 Consequently, anesthetic agents used for sedation in these procedures should ideally possess characteristics such as rapid onset, short duration of action, and hemodynamic-stabilizing properties. Dexmedetomidine is an α2-adrenergic agonist that acts on the locus coeruleus (LC), a region of the brain involved in regulating respiration and sleep. Additionally, it is known to reduce heart rate, blood pressure and biological stress response.9–11 Dexmedetomidine minimally affects respiratory rate and tidal volume in spontaneously breathing patients. 12 However, its major limitation is a relatively prolonged recovery time.13,14 Remifentanil is an opioid receptor agonist that is rapidly hydrolyzed by plasma and tissue esterases. Its short duration of action ensures the quick resolution of adverse effects and neutralization of analgesic effects. 15 A single-blinded clinical trial was conducted to minimize the undesired effects and improve recovery as well as compare the impact of dexmedetomidine and remifentanil with regard to sedation, hemodynamic alterations, analgesia, and recovery profile of patients who underwent a stereotactic brain biopsy. Methods A single-blinded clinical trial was conducted from June 2022 to July 2023 and included 140 patients aged 18–50 years who were candidates for stereotactic brain biopsy. Initially, 218 patients were assessed for eligibility, among whom 78 were excluded before randomization (66 did not meet inclusion criteria, 8 declined participation, and 4 patients were excluded for other reasons). This study adhered to the Consolidated Standards of Reporting Trials (CONSORT) 2010 checklist (Supplementary Figure 1). 16 The study was approved by the Ethics Committee of Shahid Beheshti University of Medical Sciences (IR.SBMU.RETECH.REC.1400.657; date of approval, 28 November 2021) and was registered in the Iranian Registry of Clinical Trials (code: IRCT20210415050983N2; date of approval, 09 January 2022). A preliminary version of the study was previously posted as a preprint (https://doi.org/10.21203/rs.3.rs-2745586/v1). The present article reports the complete expanded dataset and incorporates methodological clarifications and procedural refinements implemented during the extended recruitment period and subsequent scientific review. Patients were randomly assigned to the dexmedetomidine (D) or remifentanil (R) groups using a computer-generated block randomization sequence (block size, 4). Allocation concealment was ensured using sealed, opaque envelopes opened by the anesthesiology team after obtaining written informed consent. Inclusion criteria consisted of American Society of Anesthesiology (ASA) physical status class II, primary or secondary supratentorial lesions with or without hydrocephalus, a mean procedure time of 1–2 h, and patient availability for follow-ups. Focal intracranial lesions had a largest dimension <3 cm, with most located in the temporal lobe. Patients with a body mass index (BMI) of ≥35 or ≤16, self-reported alcohol or any other substance abuse, use of beta-blockers, baseline heart rate of ≤50 beats per min, uncontrolled seizures, liver or kidney dysfunction, mental disorders, indicators of a potentially difficult airway, severe neurological defects, any other uncontrolled background diseases, history of chronic pain, or brainstem lesions were excluded. Individuals with a history of craniotomy or brain ventricle drainage were also excluded. The included patients underwent a comprehensive examination, including neurological evaluations. Laboratory investigations, including hemoglobin, liver function test, renal function tests, and electrocardiography, were obtained. Upon arrival in the operating room, an 18-gauge intravenous cannula was inserted. End-tidal carbon dioxide (EtCO2), electrocardiography, oxygen saturation, and noninvasive blood pressure were monitored throughout the procedure. All patients received 2–4 L/min oxygen via nasal cannula and 5 cc/kg/h intravenous normal saline. The scalp underneath the pins was locally anesthetized with 20 mL of 1.5% lidocaine on both sides, followed by an intravenous injection of 50 µg fentanyl and 0.03 mg/kg midazolam. Subsequently, the stereotactic frames were applied with the patient in the sitting position, after which the patients were transferred to the radiology department for magnetic resonance imaging (MRI) (Figure 1). Intraoperative view of stereotactic frame-based brain biopsy using the Fischer stereotactic head frame (F.L. Fischer, Germany). The frame was uniformly applied to ensure consistent target coordinate referencing for all patients. Following the manufacturer’s protocol, all adjustments, fiducials, and targeting were performed using magnetic resonance imaging (MRI) guidance integrated into the stereotactic planning software application. Systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate were recorded at 5-min intervals. Suction, nasal airway, oral airway, laryngeal mask airway (LMA), and tracheal tube were available to manage potential airway complications. Each group comprised 70 patients. Patients in the D group received a loading dose of 0.5 µg/kg dexmedetomidine over 10 min, followed by a 0.5 µg/kg/h intravenous infusion throughout the surgery. Patients in the R group received a loading dose of 1 µg/kg intravenous boluses of remifentanil, followed by a 0.1 µg/kg/min intravenous infusion using a pump infusion. Our primary goals were to evaluate the patients’ analgesia, oxygen saturation, sedation level, and recovery profile. Hemodynamic parameters were assessed as secondary outcomes. Sedation was assessed using the Ramsay sedation scale (RSS) every 5 min, 17 with a target RSS range of 2–4 throughout the procedure. During undesired events such as bradypnea (respiratory rate less than 8 breaths per min), apnea of more than 15 s, and oxygen saturation of less than 94%, drug infusions were withheld, and respiratory support was provided as needed. All intraoperative events and postoperative complaints of pain during recovery were recorded. Drug infusions were discontinued at the end of the surgery, and patients were transferred to the postanesthesia care unit (PACU). In the PACU, sedation and pain assessments were performed every 30 min using RSS and visual analog scale (VAS) scores, respectively. Analgesia was standardized: patients with a VAS score of >3 received 2 mg morphine intravenously. All patients were closely monitored for vital signs, oxygen saturation, and adverse events until a Modified Aldrete Score of ≥9 18 was achieved, following which they were transferred to the neurosurgery department. Early postoperative follow-up included a standardized neurological examination within 6 h of surgery and an MRI within 24 h to exclude hemorrhage or other complications, in accordance with the international stereotactic neurosurgery safety protocols. The calculation of sample size was performed using G*Power software (version 3.1; Heinrich-Heine-Universität Düsseldorf; Düsseldorf, Germany). Considering the α value of 0.05 and β (Power) value of 0.80, a total of 140 patients were chosen. Statistical analyses were conducted using Statistical Package for Social Sciences software (SPSS), version 22 (IBM Corp.; Armonk, NY, USA). Normality of data distribution was assessed using the Shapiro-Wilk test. RSS scores, however, did not follow a normal distribution, and the Mann-Whitney U test was used for between-group comparisons of this variable. Descriptive statistics, repeated measures analysis of variance (ANOVA), and an independent t-test were performed. A Bonferroni-adjusted significance threshold of p < 0.0125 (0.05/4) was applied to account for multiple comparisons of primary outcomes. A p-value <0.05 was considered statistically significant for secondary and exploratory variables. Results We conducted a single-blinded controlled trial from June 2022 to July 2023 and evaluated 140 patients, including 72 males (51.4%) and 68 females (48.6%). Patients were randomized into two groups of 70 participants each. No clinically significant complications were reported among the included patients. All primary and secondary outcomes were assessed. Demographic and baseline clinical characteristics, including SBP, DBP, heart rate, and oxygen saturation, are summarized in Table 1. Table 1.Postoperative pain scores (VAS) and Morphine consumption in dexmedetomidine and remifentanil groups.. Variable D group R group P-Value 95% CI Age33.64 ± 12.3134.21 ± 13.120.79−4.82 to 3.68Weight66.64 ± 9.5769.51 ± 10.070.08−6.15 to 0.41Preoperative systolic BP115.25 ± 10.78113.88 ± 9.310.42−1.99 to 4.74Preoperative diastolic BP71.14 ± 9.1369.35 ± 11.140.30−0.35 to 7.16Preoperative heart rate87.52 ± 10.0484.52 ± 12.600.14−0.99 to 6.73Preoperative oxygen saturation96.80 ± 1.4596.94 ± 1.460.56−0.63 to 0.34D group: dexmedetomidine group; R group: remifentanil group; BP: blood pressure; CI: confidence interval. Postoperative pain scores (VAS) and Morphine consumption in dexmedetomidine and remifentanil groups.. D group: dexmedetomidine group; R group: remifentanil group; BP: blood pressure; CI: confidence interval. As shown in Table 1, there were no significant differences between the two groups in terms of age or weight. Furthermore, SBP, DBP, heart rate, and oxygen saturation did not differ significantly between the two groups. Table 2 presents the mean values of vital signs and RSS. Table 2.Mean vital signs and Ramsay sedation scores (RSS) in dexmedetomidine and remifentanil groups. Variable Group Mean P-Value RSS*Dexmedetomidine3.25 ± 0.79<0.001Remifentanil4.13 ± 0.68Systolic BPDexmedetomidine100.44 ± 8.74<0.001Remifentanil94.82 ± 9.11Diastolic BPDexmedetomidine63.59 ± 9.82<0.001Remifentanil54.00 ± 10.37Heart rateDexmedetomidine71.13 ± 13.210.012Remifentanil65.51 ± 13.56*Compared using Mann-Whitney U test due to non-normal distribution.BP: blood pressure. Mean vital signs and Ramsay sedation scores (RSS) in dexmedetomidine and remifentanil groups. *Compared using Mann-Whitney U test due to non-normal distribution. BP: blood pressure. Despite higher RSS scores in the remifentanil group, all measured vital signs were significantly higher in the D group (Table 2). Oxygen saturation was continuously monitored and remained higher than 94% in all patients throughout the procedure, and no relevant between-group difference was observed. Recovery was assessed using the Modified Aldrete Score, with a score ≥9 required for transferring to neurosurgery ward. No patient required extended recovery or intensive care admission. The dexmedetomidine group showed significantly higher mean hemodynamic parameters compared with the remifentanil group. The comparison of PACU VAS scores is presented in Table 3. VAS score was significantly lower in the D group. Total morphine consumption in the PACU was 2.17 ± 0.81 mg in the D group compared with 4.71 ± 1.09 mg in the R group, demonstrating significantly reduced requirements in the D group (p < 0.001). Table 3.Postoperative pain scores (VAS) and Morphine consumption in dexmedetomidine and remifentanil groups. Variable Group Mean ± SD P-Value 95% CI VASDexmedetomidine2.74 ± 0.77<0.001−1.85 to −1.17Remifentanil4.25 ± 1.22Morphine consumption (mg)Dexmedetomidine2.17 ± 0.81<0.001 −2.86 to −2.22Remifentanil4.71 ± 1.09CI: confidence interval; SD: standard deviation. Postoperative pain scores (VAS) and Morphine consumption in dexmedetomidine and remifentanil groups. CI: confidence interval; SD: standard deviation. Table 3 presents the postoperative pain scores (VAS) between patients receiving dexmedetomidine and remifentanil. A lower VAS score in the D group was noted, corresponding to reduced morphine requirements during recovery (p < 0.001). Discussion Stereotactic brain biopsy is a minimally invasive technique used to obtain adequate tissue sample from cerebral lesions.19,20 Frame-based stereotactic technique enables precise three-dimensional point-needle procedures, including biopsies, aspiration, and brachytherapy.21–25 This procedure must be conducted under analgesia to minimize pain and maintain patient cooperation. Additionally, the arterial pressure of carbon dioxide and oxygen must be maintained within a stable range to prevent increases in intracranial pressure. Furthermore, cardiorespiratory depression must be avoided.26–28 Dexmedetomidine is a highly selective α2-adrenoreceptor agonist that produces modest reductions in heart rate and blood pressure. It suppresses noradrenergic neurons in LC and minimally affects respiratory drive29–31 by inducing sleep-like arousable sedation.32,33 Its effects on the cardiovascular system primarily involve a minimal decrease in blood pressure and heart rate. In contrast, administering higher doses of dexmedetomidine results in hypertension and bradycardia. 31 Owing to numerous desirable effects on the nervous system, it has been utilized in neurosurgical procedures, such as deep brain stimulation, awake craniotomy, and awake fiber-optic intubation. 34 Remifentanil is an ultra-short-acting opioid that shortens the recovery time. Its adverse effects include bradycardia and postoperative hyperalgesia, which increases the need for opioid consumption. 15 We conducted a single-blinded clinical trial to investigate the effects of remifentanil and dexmedetomidine in patients undergoing stereotactic frame-based brain biopsies. To the best of our knowledge, this study is the first to compare the effects of these two anesthetics in surgical context. As illustrated, SBP, DBP, and heart rate were significantly higher in the D group. In contrast, morphine use, RSS scores, and VAS scores were lower in the D group. Additionally, postoperative pain control was superior in the D group. A meta-analysis comparing dexmedetomidine and remifentanil revealed that dexmedetomidine was associated with lower incidences of hypotension, nausea, vomiting, and immediate postoperative pain. 35 Consistently, patients in the D group demonstrated higher SBP and DBP throughout the procedure. Furthermore, postoperative opioid requirements were reduced in the D group. A comparative study was conducted on 42 patients to evaluate the effects of dexmedetomidine and remifentanil in individuals who underwent video-assisted laparoscopic cholecystectomy. The study revealed that catecholamine release during intubation and pneumoperitoneum was lower in the D group. Additionally, SBP and DBP were higher in the D group. However, no statistically significant difference in heart rate was observed between the two groups. 36 In a similar study, 90 patients undergoing laparoscopic hysterectomy were randomly assigned to receive fentanyl, remifentanil, or dexmedetomidine. VAS scores, bispectral index (BIS), and observer assessment of alertness/sedation (OAA/S) were measured. It was demonstrated that the OAA/S score was significantly lower in the D group. VAS and BIS scores were comparable across all three groups. The group that received dexmedetomidine exhibited significantly lower blood pressure and heart rate. 37 However, these findings were contradictory to those of our study. The D group exhibited higher heart rate and blood pressure, despite lower VAS scores. This discrepancy may be attributed to differences in the administered doses, as the dose of dexmedetomidine in our study was lower. Hwang et al. randomized 40 patients into two groups, R and D. They reported higher VAS scores in the R group, consistent with our findings. Additionally, they observed lower patient-controlled analgesia use and reduced postoperative nausea and vomiting in the D group. Similarly, our study demonstrated reduced postoperative opioid consumption in the D group. 38 Karabayirli et al. 39 enrolled 50 patients scheduled to undergo functional endoscopic sinus surgery (FESS) and randomized them equally into D and R groups. They compared bleeding, VAS scores, postoperative nausea and vomiting, shivering, and the need for additional analgesics between the two groups and found no statistical differences. This discrepancy could likely be explained by variations in the administered doses and the type of surgery. To compare the effects of dexmedetomidine and remifentanil, Li et al. 40 divided 44 patients scheduled for selective cesarean section into two equal groups and evaluated the BIS values, hemodynamic variables, and the amount of postoperative propofol consumption. The mean arterial pressure (MAP) increased in both groups, with a greater increase in the D group. In addition, BIS values were lower in the D group. In 2016, Rajan et al. 41 conducted a randomized, double-blinded study in patients undergoing craniotomy, in which 68 patients received dexmedetomidine and 71 received remifentanil. They reported that postoperative MAP, VAS scores, and opioid consumption were lower in the D group. Similarly, our study demonstrated reduced VAS scores in the D group. We acknowledge several drawbacks in the current study. Although the exclusion criteria were designed to ensure patient safety, they may limit the generalizability of the findings. For example, patients with abnormal BMI, those receiving beta-blockers, or those suffering from various comorbidities were excluded from the analysis. Since pain perception can be significantly influenced by psychological factors, self-reported pain scores may introduce variability. The short follow-up period, ending once the patients were transferred to the neurosurgery department after achieving a Modified Aldrete Score of ≥9, represents another limitation, as it does not account for later postoperative outcomes such as sedation or analgesia. Additionally, a low-dose regimen of dexmedetomidine may also limit the generalizability of our findings to clinical settings. Finally, although our sample size was determined using power analysis, a single-center, single-blind study may inherently introduce site-specific practices that can result in biases. Future multicenter studies with larger sample sizes and longer follow-ups are required to establish definitive results and explore the implications for broader neurosurgical practice. Although oxygen saturation and recovery were predefined as primary outcomes, they were evaluated against clinical safety and discharge thresholds rather than as continuous variables with formal between-group statistical comparison. Further studies could quantify these outcomes continuously, for example by recording time to reach a Modified Aldrete Score more than 9. Conclusions Dexmedetomidine may provide higher mean hemodynamic parameters and improved postoperative analgesia. It is also associated with lower pain scores and reduced morphine requirements compared with remifentanil in stereotactic brain biopsies. Conversely, remifentanil may provide deeper sedation but lower mean hemodynamic parameters and greater postoperative analgesia requirement. Overall, dexmedetomidine may offer a favorable alternative to remifentanil for sedation and analgesia in stereotactic brain biopsies. Supplemental Material sj-jpg-1-imr-10.1177_03000605251407890 - Supplemental material for Dexmedetomidine versus remifentanil in sedation, analgesia, and vital signs in stereotactic brain biopsy: A randomized, single-blind, active-controlled clinical trial Supplemental material, sj-jpg-1-imr-10.1177_03000605251407890 for Dexmedetomidine versus remifentanil in sedation, analgesia, and vital signs in stereotactic brain biopsy: A randomized, single-blind, active-controlled clinical trial by Faranak Behnaz, Parisa Sezari, Mohammad Mirahmadi Eraghi, Narges Bazgir and Sogol Asgari in Journal of International Medical Research